MedTrace Logo

Pembrolizumab in Refractory Advanced Esophageal Cancer

NCT02971956 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-09-21

Study results available
· View outcomes & findings →

Summary

This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer.

The study intervention involved in this study is:

-Pembrolizumab

Conditions

  • Esophageal Cancer
  • Squamous Cell Esophagus Cancer
  • Adenocarcinoma Esophagus

Interventions

DRUG

Pembrolizumab

Immune checkpoint inhibitor

Sponsors & Collaborators

Principal Investigators

  • Peter C. Enzinger, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-18
Primary Completion
2019-07-23
Completion
2020-05-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02971956 on ClinicalTrials.gov